HEIDELBERG, Germany--(BUSINESS WIRE)--Gene Bridges GmbH, the recombineering company, today announced that Chugai Pharmaceutical Co., Ltd. of Tokyo, Japan has completed the amendment to expand the commercial license agreement existing since 2005 for the use of the Red/ET recombination technology from Gene Bridges.